{"id":"NCT01248793","sponsor":"Centocor, Inc.","briefTitle":"Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Ankylosing Spondylitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2011-05","completion":"2012-03","firstPosted":"2010-11-25","resultsPosted":"2012-06-28","lastUpdate":"2013-03-20"},"enrollment":213,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ankylosing Spondylitis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Golimumab","otherNames":[]},{"type":"DRUG","name":"Golimumab (placebo group)","otherNames":[]}],"arms":[{"label":"Placebo","type":"EXPERIMENTAL"},{"label":"Golimumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese patients with ankylosing spondylitis","primaryOutcome":{"measure":"Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 14","timeFrame":"Week 14","effectByArm":[{"arm":"Group I: Placebo","deltaMin":26,"sd":null},{"arm":"Group II: Golimumab 50 mg","deltaMin":53,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":7,"countries":["China"]},"refs":{"pmids":["24729398"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":103},"commonTop":["Upper Respiratory Tract Infection","Liver Function Test Abnormal","Alanine Aminotransferase Increased","Transaminases Increased"]}}